Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection
- PMID: 25256937
- DOI: 10.1016/j.fertnstert.2014.08.013
Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection
Abstract
Objective: To evaluate the dose-response relationship of a novel recombinant human FSH (rhFSH; FE 999049) with respect to ovarian response in patients undergoing IVF/intracytoplasmic sperm injection treatment; and prospectively study the influence of initial antimüllerian hormone (AMH) concentrations.
Design: Randomized, controlled, assessor-blinded, AMH-stratified (low: 5.0-14.9 pmol/L [0.7-<2.1 ng/mL]; high: 15.0-44.9 pmol/L [2.1-6.3 ng/mL]) trial.
Setting: Seven infertility centers in four countries.
Patient(s): Two hundred sixty-five women aged ≤37 years.
Intervention(s): Controlled ovarian stimulation with either 5.2, 6.9, 8.6, 10.3, or 12.1 μg of rhFSH, or 11 μg (150 IU) of follitropin alfa in a GnRH antagonist cycle.
Main outcome measure(s): Number of oocytes retrieved.
Result(s): The number of oocytes retrieved increased in an rhFSH dose-dependent manner, from 5.2 ± 3.3 oocytes with 5.2 μg/d to 12.2 ± 5.9 with 12.1 μg/d. The slopes of the rhFSH dose-response curves differed significantly between the two AMH strata, demonstrating that a 10% increase in dose resulted in 0.5 (95% confidence interval 0.2-0.7) and 1.0 (95% confidence interval 0.7-1.3) more oocytes in the low and high AMH stratum, respectively. Fertilization rate and blastocyst/oocyte ratio decreased significantly with increasing rhFSH doses in both AMH strata. No linear relationship was observed between rhFSH dose and number of blastocysts overall or by AMH strata. Five cases of ovarian hyperstimulation syndrome were reported for the three highest rhFSH doses and in the high AMH stratum.
Conclusion(s): Increasing rhFSH doses results in a linear increase in number of oocytes retrieved in an AMH-dependent manner. The availability of blastocysts is less influenced by the rhFSH dose and AMH level.
Clinical trial registration number: NCT01426386.
Keywords: Antimüllerian hormone; blastocyst; in vitro fertilization; oocyte; ovarian response; recombinant FSH.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Randomized, assessor-blind, antimüllerian hormone-stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta.Fertil Steril. 2021 Jun;115(6):1478-1486. doi: 10.1016/j.fertnstert.2020.10.059. Epub 2020 Dec 4. Fertil Steril. 2021. PMID: 33272623 Clinical Trial.
-
Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial.Fertil Steril. 2017 Feb;107(2):387-396.e4. doi: 10.1016/j.fertnstert.2016.10.033. Epub 2016 Nov 29. Fertil Steril. 2017. PMID: 27912901 Clinical Trial.
-
Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients.Fertil Steril. 2013 May;99(6):1644-53. doi: 10.1016/j.fertnstert.2012.12.048. Epub 2013 Feb 5. Fertil Steril. 2013. PMID: 23394782 Clinical Trial.
-
Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction.Reprod Biomed Online. 2014 Feb;28(2):183-90. doi: 10.1016/j.rbmo.2013.10.012. Epub 2013 Oct 25. Reprod Biomed Online. 2014. PMID: 24368127 Review.
-
Prospective multicenter observational real-world study to assess the use, efficacy and safety profile of follitropin delta during IVF/ICSI procedures (DELTA Study).Eur J Obstet Gynecol Reprod Biol. 2024 Feb;293:21-26. doi: 10.1016/j.ejogrb.2023.12.011. Epub 2023 Dec 9. Eur J Obstet Gynecol Reprod Biol. 2024. PMID: 38100937 Review.
Cited by
-
High initial FSH dosage reduces the number of available cleavage-stage embryos in a GnRH-antagonist protocol: Real-world data of 8,772 IVF cycles from China.Front Endocrinol (Lausanne). 2022 Oct 17;13:986438. doi: 10.3389/fendo.2022.986438. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36325448 Free PMC article.
-
Mild starting dosage ovarian stimulation combined with a modified prolonged GnRH-a protocol improved IVF/ICSI outcomes in normal ovarian responders.Arch Med Sci. 2019 Sep;15(5):1294-1300. doi: 10.5114/aoms.2019.85145. Epub 2019 May 16. Arch Med Sci. 2019. PMID: 31572476 Free PMC article.
-
The role of anti-Müllerian hormone (AMH) in ovarian disease and infertility.J Assist Reprod Genet. 2020 Jan;37(1):89-100. doi: 10.1007/s10815-019-01622-7. Epub 2019 Nov 21. J Assist Reprod Genet. 2020. PMID: 31755000 Free PMC article. Review.
-
Reply: The low responder according to the POSEIDON criteria: is the prognosis really poor?Hum Reprod. 2019 Dec 1;34(12):2557-2558. doi: 10.1093/humrep/dez195. Hum Reprod. 2019. PMID: 31756245 Free PMC article. No abstract available.
-
The serum follicle stimulating hormone-to-luteinizing hormone ratios can predict assisted reproductive technology outcomes in women undergoing gonadotropin releasing hormone antagonist protocol.Front Endocrinol (Lausanne). 2023 Jan 30;14:1093954. doi: 10.3389/fendo.2023.1093954. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36793280 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical